AI Article Synopsis
- The study examined the link between specific genetic variations (SNPs) in complement genes and Alzheimer's disease biomarkers in a sample of 452 AD cases and 678 healthy controls.
- No SNPs were found to be directly associated with the overall risk of developing AD.
- However, there were notable associations between certain SNPs (rs9332739 in the C2 gene and rs4151667 in the complement factor B gene) and levels of tau protein in cerebrospinal fluid, as well as cognitive performance scores, suggesting a potential role in disease severity.
Article Abstract
The complement system has been implicated in both physiological synapse elimination and Alzheimer's disease (AD). Here, we investigated associations between four single nucleotide polymorphisms (SNPs) in complement genes and cerebrospinal fluid (CSF) biomarkers for AD in 452 neurochemically or neuropathologically verified AD cases and 678 cognitively normal controls. None of the SNPs associated with risk of AD but there were potential associations of rs9332739 in the C2 gene and rs4151667 in the complement factor B gene with CSF tau levels (p = 0.023) and Mini-Mental State Examination scores (p = 0.012), both of which may be considered markers of disease intensity/severity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/JAD-121930 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!